More than 600,000 people in UK get first Pfizer COVID-19 vaccine dose
Reuters
Published Dec 24, 2020 19:29
Updated Dec 24, 2020 21:40
By Reuters Staff
(Reuters) - More than 600,000 people in the United Kingdom have received the first dose of the Pfizer-BioNTech COVID-19 vaccine since inoculations began in the country earlier this month, the British government said on Thursday.
"The government has today published figures which show the number of people who have received the vaccine between 8 December and 20 December in the UK is 616,933," the Department of Health and Social Care said in a statement https://
Earlier this month, the United Kingdom became the first country in the world to roll out the vaccine made by Pfizer (NYSE:PFE) and BioNTech.
In all, Britain has ordered 40 million doses of Pfizer's vaccine, and Health Secretary Matt Hancock has said that he expects to receive millions of doses by the end of the year.
Vaccines have been administered to care home residents, those aged 80 and over and health and social care staff through over 500 vaccination sites, the government said.
British drugmaker AstraZeneca Plc submitted a full data package about its COVID-19 vaccine to the UK's medicines regulator, Hancock said on Wednesday.
Medicines and Healthcare Products Regulatory Agency Chief Executive June Raine told Reuters on Thursday the regulator started its analysis of the data and will make a decision in the "shortest time possible."
Separately, a spokesman for the Health Department told Reuters that some staff at the Milton Keynes testing lab, the UK's biggest, tested positive for COVID-19.
A new variant of the coronavirus has been spreading rapidly in Britain recently with huge swathes of England being placed under its strictest COVID-19 restrictions.
The variant known as the B.1.1.7 lineage may be up to 70% more infectious and more of a concern for children. It has sown chaos in Britain, prompting a wave of travel bans that are disrupting trade with Europe and threatening to further isolate the island country.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.